Giulino-Roth L, et al. - In this article, a large, multi-centre retrospective analysis of children and adults with primary mediastinal B-cell lymphoma (PMBCL) treated with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) was reported to delineate outcomes and evaluate prognostic factors. Findings demonstrated the utility of the use of DA-EPOCH-R for the treatment of PMBCL in children and adults. Researchers observed inferior outcome among patients with a positive end-of-therapy FDG-PET scan.